Global Information
회사소개 | 문의

세계의 소아용 백신 시장 : 기술, 시장 점유율, 산업 예측

Global Pediatric Vaccine Market - Technologies, Market share and Industry Forecast to 2024

리서치사 Occams Business Research & Consulting Pvt. Ltd.
발행일 2018년 09월 상품 코드 709669
페이지 정보 영문 240 Pages
가격
US $ 5,000 ₩ 5,697,000 PDF by E-mail (Single User License)
US $ 7,000 ₩ 7,975,800 PDF by E-mail (Enterprise License)


세계의 소아용 백신 시장 : 기술, 시장 점유율, 산업 예측 Global Pediatric Vaccine Market - Technologies, Market share and Industry Forecast to 2024
발행일 : 2018년 09월 페이지 정보 : 영문 240 Pages

세계의 소아용 백신(Pediatric Vaccine) 시장에 대해 조사분석했으며, 시장 개요, 시장 결정 요인, 시장 세분화, 경쟁 구도, 지역별 분석, 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 시장 개요

  • 진화와 이동
  • 시장 정의·범위
  • 산업구조
  • 규제 프레임워크
  • 종합 시장 분석
  • 추정 분석
  • 전략 분석
  • 경쟁 분석
  • 전략적 제안과 주요 결론

제3장 시장 결정 요인

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제

제4장 세계의 소아용 백신 시장 : 종류별

  • 시장 정의·범위
  • 의사결정 지원 데이터베이스·추정 방법
  • 시장 부문별 비교 분석
  • 기회 매트릭스
  • 시장 세분화

제5장 세계의 소아용 백신 시장 : 기술별

  • 시장 정의·범위
  • 의사결정 지원 데이터베이스·추정 방법
  • 시장 부문별 비교 분석
  • 기회 매트릭스
  • 시장 세분화

제6장 세계의 소아용 백신 시장 : 용도별

  • 시장 정의·범위
  • 의사결정 지원 데이터베이스·추정 방법
  • 시장 부문별 비교 분석
  • 기회 매트릭스
  • 시장 세분화

제7장 세계의 소아용 백신 시장 : 최종사용자별

  • 시장 정의·범위
  • 의사결정 지원 데이터베이스·추정 방법
  • 시장 부문별 비교 분석
  • 기회 매트릭스
  • 시장 세분화

제8장 경쟁 구도

  • 주요 전략

제9장 지역별 분석

  • 의사결정 지원 데이터베이스·추정 방법
  • 시장 부문별 비교 분석
  • 기회 매트릭스
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제10장 기업 개요

  • ASTRAZENECA.(미국)
  • BIO MED PVT. LTD.(인도)
  • CHANGCHUN CHANGSHEN LIFE SCIENCES LTD.(중국)
  • GLAXOSMITHKLINE(영국)
  • INDIAN IMMUNOLOGICALS LIMITED(인도)
  • INTERCELL AG(오스트리아)
  • MERCK SHARP & DOHME CORP.(미국)
  • MITSUBISHI TANABE PHARMA CORPORATION(일본)
  • PANACEA BIOTEC(인도)
  • PFIZER, INC.(미국)
  • SANOFI(프랑스)
  • SERUM INSTITUTE OF INDIA PVT. LTD.(인도)
  • SINOVAC BIOTECH LTD.(중국)
  • VFC CORPORATION(미국)
  • ZYDUS CADILA(인도)
KSA 18.10.09

LIST OF TABLES

  • 1. GLOBAL PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 2. GLOBAL MONOVALENT MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 3. GLOBAL MULTIVALENT MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 4. GLOBAL PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 5. GLOBAL LIVE ATTENUATED MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 6. GLOBAL INACTIVATED MARKET BY COMMERCIAL 2015-2024 ($ MILLION)
  • 7. GLOBAL SUBUNIT MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 8. GLOBAL TOXOID MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 9. GLOBAL CONJUGATE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 10. GLOBAL OTHERS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 11. GLOBAL PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 12. GLOBAL INFECTIOUS DISEASE MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 13. GLOBAL CANCER MARKET BY GHEOGRAPHY 2015-2024 ($ MILLION)
  • 14. GLOBAL ALLERGY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 15. NORTH AMERICA PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 16. EUROPE PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 17. ASIA PACIFIC PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 18. REST OF WORLD PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 19. NORTH AMERICA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 20. EUROPE PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 21. ASIA PACIFIC PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 22. REST OF WORLD PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 23. NORTH AMERICA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 24. EUROPE PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 25. ASIA PACIFIC PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 26. REST OF WORLD PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 27. NORTH AMERICA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 28. EUROPE PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 29. ASIA PACIFIC PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 30. REST OF WORLD PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 31. UNITED STATES PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 32. UNITED STATES PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 33. UNITED STATES PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 34. CANADA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 35. CANADA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 36. CANADA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 37. UK PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 38. UK PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 39. UK PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 40. FRANCE PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 41. FRANCE PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 42. FRANCE PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 43. GERMANY PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 44. GERMANY PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 45. GERMANY PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 46. SPAIN PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 47. SPAIN PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 48. SPAIN PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 49. ROE PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 50. ROE PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 51. ROE PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 52. CHINA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 53. CHINA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 54. CHINA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 55. INDIA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 56. INDIA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 57. INDIA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 58. JAPAN PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 59. JAPAN PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 60. JAPAN PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 61. AUSTRALIA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 62. AUSTRALIA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 63. AUSTRALIA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 64. ROAPAC PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 65. ROAPAC PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 66. ROAPAC PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 67. LATIN AMERICA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 68. LATIN AMERICA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 69. LATIN AMERICA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 70. MENA PEDIATRIC VACCINES MARKET BY TYPE 2015-2024 ($ MILLION)
  • 71. MENA PEDIATRIC VACCINES MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 72. MENA PEDIATRIC VACCINES MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MONOVALENT MARKET 2015-2024 ($ MILLION)
  • 2. GLOBAL MULTIVALENT MARKET 2015-2024 ($ MILLION)
  • 3. GLOBAL LIVE ATTENUATED MARKET 2015-2024 ($ MILLION)
  • 4. GLOBAL SUBUNIT MARKET 2015-2024 ($ MILLION)
  • 5. GLOBAL TOXOID MARKET 2015-2024 ($ MILLION)
  • 6. GLOBAL CONJUGATE MARKET 2015-2024 ($ MILLION)
  • 7. GLOBAL OTHERS MARKET 2015-2024 ($ MILLION)
  • 8. GLOBAL INFECTIOUS DISEASE MARKET 2015-2024 ($ MILLION)
  • 9. GLOBAL ALLERGY MARKET 2015-2024 ($ MILLION)
  • 10. UNITED STATES (U.S.) PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 11. CANADA PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 12. UNITED KINGDOM (UK) PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 13. FRANCE PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 14. GERMANY PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 15. SPAIN PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 16. ROE PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 17. INDIA PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 18. CHINA PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 19. JAPAN PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 20. AUSTRALIA PE DIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 21. ROAPAC PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 22. LATIN AMERICA PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)
  • 23. MENA PEDIATRIC VACCINES MARKET 2015-2024 ($ MILLION)

Global pediatric vaccine market is expected to grow with a CAGR of around 12.6% over the forecast period 2017-2024. Key factors contributing the growth of global pediatric vaccine market includes, rise in importance and awareness of immunization across the globe predominance of chronic diseases, technologic advancements and increase in government and non-government funding. However, cost of immunization and of healthcare infrastructure are some of the growth restricting factor in the market. Whereas, rising concern regarding diseases which are vaccine-preventable across the globe is a key opportunity in the market. Moreover, lack of awareness regarding diseases in the remote areas is expected to deliver challenge towards the market.

Rise in importance and awareness of immunization across the globe over the forecast period is the major factor attributing the growth of the market. Global governments and non-government organizations are focusing efforts regarding vaccine preventable diseases to increase awareness globally. For instance, programs by World Health Organization, Gavi, Pan America Health Organization, Center for Disease Control and Prevention etc., are providing significant awareness and aids in the immunization field to increase the healthcare in children. As the result of continuous awareness programs and immunization programs across the world, prevalence of polio has decreased in several countries almost by 99% since 1988. Only 3 countries that are Nigeria, Pakistan and Afghanistan are polio-endemic countries left. In 2016, around 86% of global children population has received 3 doses of diphtheria-tetanus-pertussis (DTP1) vaccination. Increasing vaccination programs and rising need for preventing fatal disease has significantly increased the adoption of vaccination. However, lack of healthcare infrastructure is a global pediatric vaccine major factor restricting growth of the market.

Global pediatric vaccine market is segmented into type, technology and application. On the basis of type market is segmented into monovalent and multivalent. Further on the basis of technology market is segmented into live attenuated, inactivated, subunit, toxoid, conjugate and others. Similarly, on the basis of application, global pediatric vaccines market segregated into infectious disease, cancer and allergy.

Geographically, market is segmented into North America, Asia Pacific, Europe and Rest of the world. North America is expected to dominate the global pediatric vaccine over the forecast period 2017-2024 by holding largest market share in terms of revenue. Rise in the research and development activities in the region is major factor attributing the regional market growth. Also, various investments by market players and government for increasing vaccination is expected to contribute towards the growth of the pediatric vaccine market. However, Asia Pacific is expected to register fastest growth over the forecast period 2017-2024.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL PEDIATRIC VACCINES MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATORY FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTERS 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSION
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. INCREASING AWARENESS REGARDING IMMUNIZATION
    • 3.1.2. INCREASING PREVALENCE OF CHRONIC DISEASES
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS
    • 3.1.4. GROWING GOVERNMENT SUPPORT FOR VACCINATION
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. COST OF IMMUNIZATION
    • 3.2.2. LACK OF HEALTHCARE INFRASTRUCTURE
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. RISING CONCERN AGAINST VACCINE-PREVENTABLE DISEASES
    • 3.3.2. DECREASING COST OF VACCINATION
  • 3.4. MARKET CHALLENGES
    • 3.4.1. LACK OF AWARENESS REGARDING DISEASES IN THE REMOTE AREAS

4. GLOBAL PEDIATRIC VACCINES MARKET BY TYPE

  • 4.1. MARKET DEFINITION AND SCOPE
  • 4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. MARKET SEGMENTATION
    • 4.5.1. GLOBAL MONOVALENT MARKET
      • 4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.1.3. KEY CONCLUSION
    • 4.5.2. GLOBAL MULTIVALENT MARKET
      • 4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.2.3. KEY CONCLUSION

5. GLOBAL PEDIATRIC VACCINES MARKET BY TECHNOLOGY

  • 5.1. MARKET DEFINITION AND SCOPE
  • 5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 5.4. OPPORTUNITY MATRIX
  • 5.5. MARKET SEGMENTATION
    • 5.5.1. GLOBAL LIVE ATTENUATED MARKET
      • 5.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.1.3. KEY CONCLUSION
    • 5.5.2. GLOBAL INACTIVATED MARKET
      • 5.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.2.3. KEY CONCLUSION
    • 5.5.3. GLOBAL SUBUNIT MARKET
      • 5.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.3.3. KEY CONCLUSION
    • 5.5.4. GLOBAL TOXOID MARKET
      • 5.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.4.3. KEY CONCLUSION
    • 5.5.5. GLOBAL CONJUGATE MARKET
      • 5.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.5.3. KEY CONCLUSION
    • 5.5.6. GLOBAL OTHERS MARKET
      • 5.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.6.3. KEY CONCLUSION

6. GLOBAL PEDIATRIC VACCINES MARKET BY APPLICATION

  • 6.1. MARKET DEFINITION AND SCOPE
  • 6.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.4. OPPORTUNITY MATRIX
  • 6.5. MARKET SEGMENTATION
    • 6.5.1. GLOBAL INFECTIOUS DISEASE MARKET
      • 6.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.1.3. KEY CONCLUSION
    • 6.5.2. GLOBAL CANCER MARKET
      • 6.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.2.3. KEY CONCLUSION
    • 6.5.3. GLOBAL ALLERGY MARKET
      • 6.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.3.3. KEY CONCLUSION

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIES
    • 7.1.1. LIST OF MERGERS AND ACQUISITIONS
    • 7.1.2. LIST OF JOINT VENTURES
    • 7.1.3. LIST OF PRODUCT LAUNCHES
    • 7.1.4. LIST OF PARTNERSHIPS

8. GEOGRAPHIC ANALYSIS

  • 8.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 8.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 8.3. OPPORTUNITY MATRIX
  • 8.4. GLOBAL PEDIATRIC VACCINES MARKET BY REGION 2015-2024
    • 8.4.1. NORTH AMERICA
      • 8.4.1.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 8.4.1.2. TOP COUNTRY ANALYSIS
        • 8.4.1.2.1. U.S.
          • 8.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.1.2.1.2. KEY CONCLUSION
        • 8.4.1.2.2. CANADA
          • 8.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.1.2.2.2. KEY CONCLUSION
    • 8.4.2. EUROPE
      • 8.4.2.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 8.4.2.2. TOP COUNTRY ANALYSIS
        • 8.4.2.2.1. UK
          • 8.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.1.2. KEY CONCLUSION
        • 8.4.2.2.2. FRANCE
          • 8.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.2.2. KEY CONCLUSION
        • 8.4.2.2.3. GERMANY
          • 8.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.3.2. KEY CONCLUSION
        • 8.4.2.2.4. SPAIN
          • 8.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.4.2. KEY CONCLUSION
        • 8.4.2.2.5. REST OF EUROPE
          • 8.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.5.2. KEY CONCLUSION
  • 8.4.3. ASIA PACIFIC
    • 8.4.3.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
    • 8.4.3.2. TOP COUNTRY ANALYSIS
      • 8.4.3.2.1. CHINA
        • 8.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.3.2.1.2. KEY CONCLUSION
      • 8.4.3.2.2. INDIA
        • 8.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.3.2.2.2. KEY CONCLUSION
      • 8.4.3.2.3. JAPAN
        • 8.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.3.2.3.2. KEY CONCLUSION
      • 8.4.3.2.4. AUSTRALIA
        • 8.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.3.2.4.2. KEY CONCLUSION
      • 8.4.3.2.5. REST OF ASIA PACIFIC
        • 8.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.3.2.5.2. KEY CONCLUSION
  • 8.4.4. ROW
    • 8.4.4.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
    • 8.4.4.2. TOP COUNTRY ANALYSIS
      • 8.4.4.2.1. LATIN AMERICA
        • 8.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.4.2.1.2. KEY CONCLUSION
      • 8.4.4.2.2. MIDDLE EAST & AFRICA
        • 8.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
        • 8.4.4.2.2.2. KEY CONCLUSION

9. COMPANY PROFILES

  • 9.1. ASTRAZENECA. (U.S.)
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. STRATEGIC INITIATIVES
    • 9.1.4. SCOT ANALYSIS
    • 9.1.5. STRATEGIC ANALYSIS
  • 9.2. BIO MED PVT. LTD. (INDIA)
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. STRATEGIC INITIATIVES
    • 9.2.4. SCOT ANALYSIS
    • 9.2.5. STRATEGIC ANALYSIS
  • 9.3. CHANGCHUN CHANGSHEN LIFE SCIENCES LTD. (CHINA)
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. STRATEGIC INITIATIVES
    • 9.3.4. SCOT ANALYSIS
    • 9.3.5. STRATEGIC ANALYSIS
  • 9.4. GLAXOSMITHKLINE (U.K.)
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. STRATEGIC INITIATIVES
    • 9.4.4. SCOT ANALYSIS
    • 9.4.5. STRATEGIC ANALYSIS
  • 9.5. INDIAN IMMUNOLOGICALS LIMITED (INDIA)
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. STRATEGIC INITIATIVES
    • 9.5.4. SCOT ANALYSIS
    • 9.5.5. STRATEGIC ANALYSIS
  • 9.6. INTERCELL AG (AUSTRIA)
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. STRATEGIC INITIATIVES
    • 9.6.4. SCOT ANALYSIS
    • 9.6.5. STRATEGIC ANALYSIS
  • 9.7. MERCK SHARP & DOHME CORP. (U.S.)
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. STRATEGIC INITIATIVES
    • 9.7.4. SCOT ANALYSIS
    • 9.7.5. STRATEGIC ANALYSIS
  • 9.8. MITSUBISHI TANABE PHARMA CORPORATION (JAPAN)
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. STRATEGIC INITIATIVES
    • 9.8.4. SCOT ANALYSIS
    • 9.8.5. STRATEGIC ANALYSIS
  • 9.9. PANACEA BIOTEC (INDIA)
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. STRATEGIC INITIATIVES
    • 9.9.4. SCOT ANALYSIS
    • 9.9.5. STRATEGIC ANALYSIS
  • 9.10. PFIZER, INC. (U.S.)
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. STRATEGIC INITIATIVES
    • 9.10.4. SCOT ANALYSIS
    • 9.10.5. STRATEGIC ANALYSIS
  • 9.11. SANOFI (FRANCE)
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. STRATEGIC INITIATIVES
    • 9.11.4. SCOT ANALYSIS
    • 9.11.5. STRATEGIC ANALYSIS
  • 9.12. SERUM INSTITUTE OF INDIA PVT. LTD. (INDIA)
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. STRATEGIC INITIATIVES
    • 9.12.4. SCOT ANALYSIS
    • 9.12.5. STRATEGIC ANALYSIS
  • 9.13. SINOVAC BIOTECH LTD. (CHINA)
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. STRATEGIC INITIATIVES
    • 9.13.4. SCOT ANALYSIS
    • 9.13.5. STRATEGIC ANALYSIS
  • 9.14. VFC CORPORATION (U.S.)
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. STRATEGIC INITIATIVES
    • 9.14.4. SCOT ANALYSIS
    • 9.14.5. STRATEGIC ANALYSIS
  • 9.15. ZYDUS CADILA (INDIA)
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. STRATEGIC INITIATIVES
    • 9.15.4. SCOT ANALYSIS
    • 9.15.5. STRATEGIC ANALYSIS
Back to Top
전화 문의
이용안내
 
BCC Research